MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Arcus Biosciences Inc

Fermé

SecteurSoins de santé

15.04 7.74

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.15

Max

15.15

Chiffres clés

By Trading Economics

Ventes

132M

160M

Employés

627

EBITDA

126M

4M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+119.61% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

566M

1.5B

Ouverture précédente

7.3

Clôture précédente

15.04

Score Technique

By Trading Central

Confiance

Neutral Evidence

Arcus Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 oct. 2025, 20:45 UTC

Résultats

Costco Wholesale Sales Climb in September, Early October

8 oct. 2025, 20:12 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 oct. 2025, 16:39 UTC

Principaux Mouvements du Marché

Mining Shares Rise as Gold Prices Soar

8 oct. 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 oct. 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8 oct. 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Finance Acquisition Using Internal Funds

8 oct. 2025, 23:17 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 oct. 2025, 23:16 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 oct. 2025, 21:54 UTC

Market Talk
Résultats

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 oct. 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 oct. 2025, 21:26 UTC

Market Talk
Résultats

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 oct. 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 oct. 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs Will Remain a Publicly Traded Co >TASK

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 oct. 2025, 18:45 UTC

Acquisitions, Fusions, Rachats

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 oct. 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 oct. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

8 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 oct. 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 oct. 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 oct. 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 oct. 2025, 15:44 UTC

Acquisitions, Fusions, Rachats

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 oct. 2025, 15:44 UTC

Acquisitions, Fusions, Rachats

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 oct. 2025, 15:43 UTC

Acquisitions, Fusions, Rachats

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 oct. 2025, 15:42 UTC

Acquisitions, Fusions, Rachats

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparaison

Variation de prix

Arcus Biosciences Inc prévision

Objectif de Prix

By TipRanks

119.61% hausse

Prévisions sur 12 Mois

Moyen 31.8 USD  119.61%

Haut 52 USD

Bas 14 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

9

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

8.01 / 8.75Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Neutral Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat